Ipsen – Monthly information relative to the total number of voting rights and shares composing the share capital
Monthly information relative to the total number of voting rights
and shares composing the share capital
(in accordance with Article L.233-8 II of the French Commercial Code and
Article 223-16 of the General Regulation of the Autorité des Marchés Financiers)
Market: Euronext Paris
ISIN Code: FR 0010259150
LEI: 549300M6SGDPB4Z94P11
| Date | Total number of shares composing the share capital | Total number of voting rights (1) |
| 30 June 2023 | 83,814,526 | Gross total* of voting rights: 132,122,911 |
| Net total** of voting rights: 131,177,206 |
(1) Existence of a statutory clause imposing an obligation to declare threshold crossing complementary to the one relative to the legal thresholds (Article 10).
* Gross total = total number of voting rights attached to the total number of shares, including the number of shares which benefit of double voting rights and the number of treasury shares. The « Gross total » is used as a basis for the calculation of threshold crossings.
** Net total = total number of voting rights attached to the total number of shares – shares without voting rights.
Attachments
- Declaration relative to the total number of voting rights – June 2023
- Declaration relative to the total number of voting rights – June 2023
Ipsen appoints Michelle C. Werner as EVP, President of North America
Ipsen’s Onivyde® regimen, a potential new standard-of-care first-line therapy in metastatic pancreatic adenocarcinoma, approved by FDA
Ipsen confirms U.S. FDA grants priority review for New Drug Application for elafibranor for the treatment of rare cholestatic liver disease, PBC
US FDA approves Ipsen’s Sohonos™ (palovarotene) capsules, the first and only treatment for people with fibrodysplasia ossificans progressiva
IPSEN – Buy-back programme – Art 5 of MAR – Week 27 – 2023
Ipsen – Half year statement – 2023 06 30
IPSEN – Buy-back programme – Art 5 of MAR – Week 26 – 2023
Ipsen and GENFIT Announce Positive Results from Phase III ELATIVE trial of elafibranor in patients with primary biliary cholangitis, a rare cholestatic liver disease
Ipsen announces positive outcome of FDA Advisory Committee on investigational palovarotene for fibrodysplasia ossificans progressiva
IPSEN – Buy-back programme – Art 5 of MAR – Week 25 – 2023